24 0


/ Sales ,63x Nbr of Employees 160 Free-Float 93,2% More FinancialsCompanyEnanta Pharmaceuticals, Inc. is a biotechnology company. The Company has discovered glecaprevir, a protease inhibitor… Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus , hepatitis B virus , and non-alcoholic steatohepatitis diseases. The firm also conducts research in human metapneumovirus and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta today announced a new research program with broader spectrum antiviral activity, targeting hMPV and RSV with a single agent, which Enanta refers to as a dual-inhibitor. In preclinical studies, these dual-inhibitors maintained activity against multiple genotypes and strains of hMPV and RSV in a range of cell types. Enanta expects to select a clinical dual hMPV/RSV candidate in the fourth quarter of 2023. Enanta is also currently evaluating EDP-323, a novel, oral, direct-acting antiviral selectively targeting the RSV L-protein, for the treatment of RSV, in a Phase 1 study. This double-blind, placebo-controlled, first-in-human study will enroll approximately 80 healthy subjects to evaluate the safety, tolerability, and PK of EDP-323.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Enanta today announced new preclinical in vivo data on EDP-235 highlighting the robust antiviral treatment effect and prevention of COVID-19 transmission in a ferret model. In a study, ferrets were infected with SARS-CoV-2 and then subsequently received either EDP-235 or vehicle. Results demonstrated that EDP-235 treatment of SARS-CoV-2 infected animals resulted in a rapid, robust and sustained decline in viral replication. To understand the effect of EDP-235 on transmission, cohorts of infected animals who had been treated with EDP-235 were co-housed with healthy and untreated animals and monitored for infection. Results showed that healthy animals did not contract COVID-19 when co-housed with infected animals that were treated with EDP-235, whereas the healthy animals co-housed with vehicle-treated infected animals did contract the virus.

The company’s shares opened today at $46.71.According to TipRanks, Buch… The company’s shares opened today at $48.13.Buchanan covers the Healthc… Enanta remains committed to developing a cure for HBV patients and is currently focused on identifying additional compounds with different mechanisms of action to combine with EDP-514, its potent core inhibitor, and a nucleoside reverse transcriptase inhibitor. EDP-514, which received Fast Track designation from the FDA, has displayed a good safety profile and robust antiviral activity in multiple HBV patient populations, with significant declines in HBV DNA among the best published to date for core inhibitors. Shares of Enanta Pharmaceuticals Inc. slid 19.3% in premarket trading on Thursday, the day after the company said its experimental treatment for respiratory syncytial virus did not meet the primary endpoint in a Phase 2b …

The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued. Enanta Pharmaceuticals, Inc. recently announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $14.00 per share. The shares of Enanta’s common stock will trade on the NASDAQ Global Select Market under the symbol ENTA beginning on March 21, 2013.

Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. There’s a lot to be optimistic whitewalker 121 about in the Healthcare sector as 3 analysts just weighed in on Enanta Pharmaceuticals (ENTA – Research Report), Mirati Therapeutics (MRTX – Research Report) and LAVA Therapeutics (LVTX – Res… Measures how much net income or profit is generated as a percentage of revenue.